Confident Investing Starts With TipRanks Premium

Get 55% Off
TipRanks
Go Ultimate55% OFF

Medicenna Therapeutics Corp (MDNA) Stock Price & Analysis

223 Followers

MDNA Stock Chart & Stats

CA$0.42-CA$0.01(-2.35%)
At close: 4:00 PM EST
C$0.4C$0.45Aug 10Aug 24Sep 8Sep 21Oct 5Oct 19Nov 2
Day’s Range
CAD 0.41 - CAD 0.45
52-Week Range
CAD 0.34 - CAD 1.78
Previous Close
CAD 0.43
Volume
N/A
Average Volume (3M)
49.33K
Market Cap
CAD 32.99M
Enterprise Value
CAD 28.64M
Total Cash (Recent Filing)
CAD 5.69M
Total Debt (Recent Filing)
CAD 104.00K
Price to Earnings (P/E)
―
Beta
1.69
Next Earnings
Nov 12, 2026 (Est.)
EPS Estimate
-0.04
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Low Financial Leverage

Very low debt limits interest obligations and preserves some financial flexibility while the company advances its clinical programs. Although the shrinking equity base remains a concern, modest leverage reduces balance-sheet pressure compared with a highly indebted biotechnology developer.

Engineered Cytokine Platform

A platform aimed at improving both efficacy and tolerability could support multiple therapeutic candidates rather than relying on a single asset. If clinical results validate the design approach, this technology may provide a durable foundation for future oncology and immune-disease development.

Multiple Clinical Programs

Having lead candidates across more than one cytokine pathway gives Medicenna several potential development opportunities within oncology. This breadth can improve the company’s strategic flexibility, provided clinical progress eventually demonstrates value across the programs.

Bears Say

No Product Revenue

Without an approved product, Medicenna has no recurring commercial revenue base to fund research, trials, or corporate costs. Its financial outlook therefore remains dependent on external financing or future partnering, making progress toward commercialization a critical long-term requirement.

Persistent Large Losses

Large and worsening operating losses show that current spending materially exceeds available income and that profitability has not yet stabilized. Continued losses can consume capital before clinical programs mature, increasing the importance of successful development and disciplined expense management.

Cash Burn And Shrinking Equity

Sustained negative operating and free cash flow indicates the business is consuming cash rather than funding itself. Combined with the sharply reduced equity base, this weakens the capital cushion and raises the likelihood that future financing could be needed, potentially creating dilution pressure.

Medicenna Therapeutics Corp News

MDNA FAQ

What was Medicenna Therapeutics Corp’s price range in the past 12 months?
Medicenna Therapeutics Corp lowest stock price was C$0.34 and its highest was C$1.78 in the past 12 months.
What is Medicenna Therapeutics Corp’s market cap?
Medicenna Therapeutics Corp’s market cap is C$32.99M.
When is Medicenna Therapeutics Corp’s upcoming earnings report date?
Medicenna Therapeutics Corp’s next earnings report is estimated for Nov 12, 2026 (not yet confirmed), which is in 8 days.
How were Medicenna Therapeutics Corp’s earnings last quarter?
Medicenna Therapeutics Corp released its earnings results on Aug 14, 2026. The company reported -C$0.06 earnings per share for the quarter, missing the consensus estimate of -C$0.057 by -C$0.003.
Is Medicenna Therapeutics Corp overvalued?
Not enough analysts have published a price target to calculate whether the price is overvalued.
Does Medicenna Therapeutics Corp pay dividends?
Medicenna Therapeutics Corp does not currently pay dividends.
What is Medicenna Therapeutics Corp’s EPS estimate?
Medicenna Therapeutics Corp’s EPS estimate is -0.04.
How many shares outstanding does Medicenna Therapeutics Corp have?
Medicenna Therapeutics Corp has 77,617,340 shares outstanding.
What happened to Medicenna Therapeutics Corp’s price movement after its last earnings report?
Medicenna Therapeutics Corp reported an EPS of -C$0.06 in its last earnings report, missing expectations of -C$0.057. Following the earnings report the stock price went up 15%.
Which hedge fund is a major shareholder of Medicenna Therapeutics Corp?
Currently, no hedge funds are holding shares in TSE:MDNA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology